Email this article Dannye dolgosrochnogo nablyudeniya podtverzhdayut, chto razrabotannyy kompaniey Novartispreparat TasignaR prevoskhodit preparat GlivekR po snizheniyu riska progressirovaniyazabolevaniya u patsientov s vpervye diagnostirovannym khronicheskim mieloleykozom
- Authors: - -
- Issue: Vol 13, No 1 (2011)
- Pages: 7-8
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/29421
- ID: 29421
Cite item
